Wealth Enhancement Advisory Services LLC Has $10.29 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

Wealth Enhancement Advisory Services LLC lowered its position in shares of Kenvue Inc. (NYSE:KVUE) by 0.2% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 479,677 shares of the company’s stock after selling 963 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Kenvue were worth $10,294,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of KVUE. Planned Solutions Inc. bought a new stake in Kenvue during the fourth quarter worth $27,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in shares of Kenvue in the 4th quarter valued at approximately $28,000. Mather Group LLC. acquired a new position in Kenvue during the 1st quarter worth approximately $28,000. CVA Family Office LLC acquired a new position in Kenvue during the 4th quarter worth approximately $32,000. Finally, Pinnacle Bancorp Inc. boosted its position in Kenvue by 51.3% in the fourth quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock valued at $33,000 after buying an additional 526 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on KVUE. William Blair started coverage on Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating for the company. Citigroup reissued a “neutral” rating and set a $21.00 price target on shares of Kenvue in a research note on Tuesday, May 28th. HSBC upped their price objective on Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a research note on Wednesday, May 8th. Finally, Sanford C. Bernstein initiated coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Kenvue presently has an average rating of “Hold” and an average price target of $23.09.

Kenvue Price Performance

KVUE stock opened at $18.18 on Friday. The firm has a market cap of $34.81 billion and a price-to-earnings ratio of 23.31. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.66. The company’s fifty day simple moving average is $19.19 and its 200 day simple moving average is $19.98. Kenvue Inc. has a 12-month low of $17.75 and a 12-month high of $26.66.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03. The company had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The company’s revenue was down 24.9% compared to the same quarter last year. On average, analysts expect that Kenvue Inc. will post 1.17 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.40%. The ex-dividend date was Tuesday, May 7th. Kenvue’s dividend payout ratio is currently 102.56%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.